Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $22.11.

NMRA has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, September 12th. Royal Bank of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, Mizuho started coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price for the company.

Neumora Therapeutics Trading Down 1.2 %

NASDAQ NMRA opened at $12.92 on Tuesday. Neumora Therapeutics has a 12 month low of $8.33 and a 12 month high of $21.00. The company’s 50 day simple moving average is $11.87 and its 200 day simple moving average is $11.22.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). On average, sell-side analysts anticipate that Neumora Therapeutics will post -1.51 EPS for the current fiscal year.

Insider Transactions at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Neumora Therapeutics news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at $1,821,871.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the transaction, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. The disclosure for this sale can be found here. Insiders sold 90,926 shares of company stock valued at $1,067,758 over the last three months. 26.40% of the stock is owned by corporate insiders.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank lifted its stake in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the last quarter. Quarry LP acquired a new position in Neumora Therapeutics during the 2nd quarter worth $98,000. SkyOak Wealth LLC bought a new stake in Neumora Therapeutics during the second quarter valued at about $147,000. Principal Financial Group Inc. bought a new stake in Neumora Therapeutics during the second quarter valued at about $166,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at about $566,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.